Clarke-A-Clinical-Guide-To-Inherited

Total Page:16

File Type:pdf, Size:1020Kb

Clarke-A-Clinical-Guide-To-Inherited This page intentionally left blank A Clinical Guide to Inherited Metabolic Diseases This user-friendly clinical handbook provides a clear and concise overview of how to go about recognizing and diagnosing inherited metabolic diseases. The reader is led through the diagnostic process from the identification of those features of an illness suggesting that it might be metabolic through the selection of appropriate laboratory investigation to a final diagnosis. The book is organized into chapters according to the most prominent presenting problem of patients with inherited metabolic diseases: neurologic, hepatic, cardiac, metabolic acidosis, dysmorphism, and acute catastrophic illness in the newborn. It also includes chapters on general principles, laboratory investigation, neonatal screening, and the principles of treatment. This new edition includes much greater depth on mitochondrial disease and congenital disor- ders of glycosylation. The chapters on neurological syndrome and newborn screening are greatly expanded, as are those on laboratory investigation and treatment, to take account of the very latest technological developments. Dr J. T. R. Clarke is Professor of Paediatrics at the University of Toronto and a Senior Associate Scientist in the Research Institute of the Hospital for Sick Children, as well as continuing Head of the Genetic Metabolic Diseases Program of the Hospital. He is a Fellow of the Royal College of Physicians of Canada and the Canadian College of Medical Geneticists. He has won awards for postgraduate paediatric teaching and for excellence in paediatric medical care. He is consulted extensively by government and industry on matters relating to the management of inherited metabolic diseases and newborn screening. He is internationally respected for his expertise in the general area of metabolic genetics and is widely sought as a speaker and educator in this field. He has given over 100 invited lectures on inherited metabolic diseases in countries around the globe. This page intentionally left blank A Clinical Guide to Inherited Metabolic Diseases Third Edition JoeT.R.Clarke, MD, PhD, FRCPC Division of Clinical & Metabolic Genetics, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8 CANADA cambridge university press Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo Cambridge University Press The Edinburgh Building, Cambridge cb2 2ru,UK Published in the United States of America by Cambridge University Press, New York www.cambridge.org Informationonthistitle:www.cambridge.org/9780521614993 © Joe T.R.Clarke 2005 This publication is in copyright. Subject to statutory exception and to the provision of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press. First published in print format 2005 isbn-13 978-0-511-13453-1 eBook (MyiLibrary) isbn-10 0-511-13453-3 eBook (MyiLibrary) isbn-13 978-0-521-61499-3 paperback isbn-10 0-521-61499-6 paperback Cambridge University Press has no responsibility for the persistence or accuracy of urls for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate. Contents Reviewsoffirstedition page x Reviews ofsecond edition xi List of tables xii List of figures xvi Preface xix 1General principles 1 Introduction 1 Some general metabolic concepts 2 Disease results from point defects in metabolism 4 Accumulation of substrate 4 Accumulation of a normally minor metabolite 6 Deficiency of product 7 Secondary metabolic phenomena 9 Inborn errors of metabolism are inherited 9 Autosomal recessive disorders 9 X-linked recessive disorders 11 Autosomal dominant disorders 13 Mitochondrial inheritance 14 Inherited metabolic diseases may present at any age 16 Three sources of diagnostic confusion 17 Confusion with common acquired conditions 17 Confusion caused by association with intercurrent illness 20 Confusion arising from genetic heterogeneity 21 Congenital malformations and inborn errors of metabolism 21 The internet is particularly important 21 Suggested reading 27 2Neurologic syndrome 28 Chronic encephalopathy – without non-neural involvement 29 Gray matter disease (poliodystrophy) 29 Psychomotor retardation or dementia 29 Seizures 34 White matter disease (leukodystrophy) 47 v vi Contents Chronic encephalopathy – with non-neural tissue involvement 50 Acute encephalopathy 53 Hyperammonemia 55 Leucine encephalopathy (maple syrup urine disease – MSUD) 61 Reye-like acute encephalopathy (fatty acid oxidation defects) 61 Acute encephalopathy with metabolic acidosis 63 Hypoglycemia 63 Stroke 63 Movement disorder 63 Ataxia 63 Choreoathetosis and dystonia 69 Parkinsonism 71 Myopathy 72 Acute intermittent muscle weakness 72 Progressive muscle weakness 73 Myoglobinuria (myophosphorylase deficiency phenotype) 74 Myoglobinuria (CPT II deficiency phenotype) 77 Myopathy as a manifestation of multisystem disease (mitochondrial myopathies) 77 Autonomic dysfunction 79 Psychiatric problems 79 Suggested reading 87 3Metabolic acidosis 90 Buffers, ventilation, and the kidney 90 Is the metabolic acidosis the result of abnormal losses of bicarbonate or accumulation of acid? 92 Metabolic acidosis caused by abnormal bicarbonate losses 92 Metabolic acidosis resulting from accumulation of organic anion 94 Lactic acidosis 94 Pyruvate accumulation 95 PDH deficiency 98 PC deficiency 99 Multiple carboxylase deficiency 99 NADH accumulation 100 Ketoacidosis 101 Mitochondrial acetoacetyl-CoA thiolase deficiency (␤-ketothiolase deficiency) 102 Succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency 103 Organic aciduria 104 Methylmalonic acidemia (MMA) 104 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase deficiency 110 Glutaric aciduria 110 Dicarboxylic aciduria 112 Ethylmalonic aciduria 113 D-Lactic acidosis 113 vii Contents Adventitious organic aciduria 114 Suggested reading 115 4Hepatic syndrome 116 Jaundice 116 Unconjugated hyperbilirubinemia 116 Conjugated hyperbilirubinemia 118 Hepatomegaly 118 Hypoglycemia 120 Ways to increase glucose production 120 Ways to decrease peripheral glucose utilization 122 An approach to the differential diagnosis of hypoglycemia 125 Hepatocellular dysfunction 133 Investigation 139 Liver function tests 139 Fasting tests 139 Suggested reading 141 5Cardiac syndromes 143 Cardiomyopathy 143 Initial investigation of possible inherited metabolic cardiomyopathy 148 Glycogen storage disease, type II (GSD II or Pompe disease) 149 Primary systemic carnitine deficiency 151 Fabry disease 151 Mitochondrial cardiomyopathies 152 Arrhythmias 153 Coronary artery disease 155 Familial hypercholesterolemia 155 Suggested reading 159 6Storage syndrome and dysmorphism 162 General characteristics of the dysmorphism resulting from inborn errors of metabolism 162 What are the types of inherited metabolic diseases in which dysmorphism might be expected to be prominent? 164 Lysosomal disorders 165 Peroxisomal disorders 178 Mitochondrial disorders 182 Biosynthetic defects 183 What sort of metabolic studies are most likely to be diagnostically productive in the investigation of dysmorphism? 195 Suggested reading 196 7Acute metabolic illness in the newborn 198 Suspicion 198 Initial laboratory investigation 200 Five clinical ‘syndromes’ 202 viii Contents Encephalopathy without metabolic acidosis 203 Maple syrup urine disease (MSUD) 203 Urea cycle enzyme defects (UCED) 205 Nonketotic hyperglycinemia (NKHG) 208 Pyridoxine-dependent seizures 209 Peroxisomal disorders (Zellweger syndrome) 209 Molybdenum cofactor deficiency (sulfite oxidase/xanthine oxidase deficiency 209 Encephalopathy with metabolic acidosis 210 Organic acidurias 210 Congenital lactic acidosis 213 Dicarboxylic aciduria 214 Neonatal hepatic syndrome 215 Jaundice 215 Severe hepatocellular dysfunction 217 Hypoglycemia 220 Cardiac syndrome 222 Intractable cardiac arrhythmias 222 Cardiomyopathy 222 Nonimmune fetal hydrops 223 Initial management 223 Summary comments 226 Suggested reading 226 8Newborn screening 228 Screening for medical intervention 230 Screening for reproductive planning 230 Screening to answer epidemiological questions 231 Case-finding 232 Problems created by false positive screening tests 232 Screening technology 233 Bacterial inhibition assays – the ‘Guthrie test’ 233 Tandem MSMS 235 Radioimmunoassay 238 Enzyme assay 238 Specific mutation testing 239 Suggested reading 239 9 Laboratory investigation 241 Studies on the extent and severity of pathology 245 Studies directed at the classification of disease processes (the ‘metabolic screen’) 245 Investigation of ‘small molecule disease’ 246 Plasma ammonium 246 Plasma lactate and pyruvate 246 Plasma ketones and free fatty acids 246 Amino acid analysis 247 Neurotransmitters 253 Organic acid analysis 254 Acylcarnitines and acylglycines 256 Porphyrins 260 Approaches to the investigation of metabolic disorders 263 ix Contents Cellular metabolic screening studies 263 Provocative testing 267 Enzymology 270 Molecular genetic studies 271 Investigation of ‘organelle disease’ 274 Lysosomal disorders 274 Disorders of mitochondrial energy metabolism 285 Peroxisomal disorders 291 Suggested reading 295 10 Treatment 297 Control of accumulation of substrate 297 Restricted dietary intake 297 Control of endogenous production of substrate 301 Acceleration of removal of substrate 303 Replacement of product 306 Reaction product replacement 306 Gene product replacement 307 Gene product
Recommended publications
  • Effect of Propionic Acid on Fatty Acid Oxidation and U Reagenesis
    Pediat. Res. 10: 683- 686 (1976) Fatty degeneration propionic acid hyperammonemia propionic acidemia liver ureagenesls Effect of Propionic Acid on Fatty Acid Oxidation and U reagenesis ALLEN M. GLASGOW(23) AND H. PET ER C HASE UniversilY of Colorado Medical Celller, B. F. SlOlillsky LaboralOries , Denver, Colorado, USA Extract phosphate-buffered salin e, harvested with a brief treatment wi th tryps in- EDTA, washed twice with ph os ph ate-buffered saline, and Propionic acid significantly inhibited "CO z production from then suspended in ph os ph ate-buffe red saline (145 m M N a, 4.15 [I-"ejpalmitate at a concentration of 10 11 M in control fibroblasts m M K, 140 m M c/, 9.36 m M PO" pH 7.4) . I n mos t cases the cells and 100 11M in methyl malonic fibroblasts. This inhibition was we re incubated in 3 ml phosph ate-bu ffered sa lin e cont aining 0.5 similar to that produced by 4-pentenoic acid. Methylmalonic acid I1Ci ll-I4Cj palm it ate (19), final concentration approximately 3 11M also inhibited ' 'C0 2 production from [V 'ejpalmitate, but only at a added in 10 II I hexane. Increasing the amount of hexane to 100 II I concentration of I mM in control cells and 5 mM in methyl malonic did not impair palmit ate ox id ation. In two experiments (Fig. 3) the cells. fibroblasts were in cub ated in 3 ml calcium-free Krebs-Ringer Propionic acid (5 mM) also inhibited ureagenesis in rat liver phosphate buffer (2) co nt ain in g 5 g/ 100 ml essent iall y fatty ac id slices when ammonia was the substrate but not with aspartate and free bovine se rum albumin (20), I mM pa lm itate, and the same citrulline as substrates.
    [Show full text]
  • Propionic Acidemia: an Extremely Rare Cause of Hemophagocytic Lymphohistiocytosis in an Infant
    Case report Arch Argent Pediatr 2020;118(2):e174-e177 / e174 Propionic acidemia: an extremely rare cause of hemophagocytic lymphohistiocytosis in an infant Sultan Aydin Kökera, MD, Osman Yeşilbaşb, MD, Alper Kökerc, MD, and Esra Şevketoğlud, Assoc. Prof. ABSTRACT INTRODUCTION Hemophagocytic lymphohystiocytosis (HLH) may be primary Hemophagocytic lymphohistiocytosis (inherited/familial) or secondary to infections, malignancies, rheumatologic disorders, immune deficiency syndromes (HLH) is a life-threatening disorder in and metabolic diseases. Cases including lysinuric protein which there is uncontrolled proliferation of intolerance, multiple sulfatase deficiency, galactosemia, activated lymphocytes and histiocytes. The Gaucher disease, Pearson syndrome, and galactosialidosis have diagnosis of HLH is based on fulfilling at least previously been reported. It is unclear how the metabolites trigger HLH in metabolic diseases. A 2-month-old infant five of eight criteria (fever, splenomegaly, with lethargy, pallor, poor feeding, hepatosplenomegaly, bicytopenia, hypertriglyceridemia and/ fever and pancytopenia, was diagnosed with HLH and the or hypofibrinogenemia, hemophagocytosis, HLH-2004 treatment protocol was initiated. Analysis for low/absent natural killer cell activity, primary HLH gene mutations and metabolic screening tests were performed together; primary HLH gene mutations were hyperferritinemia, and high soluble interleukin- negative, but hyperammonemia and elevated methyl citrate 2-receptor levels). HLH includes both familial were detected. Propionic acidemia was diagnosed with tandem and reactive disease triggered by infection, mass spectrometry in neonatal dried blood spot. We report this immunologic disorder, malignancy, or drugs. case of HLH secondary to propionic acidemia. Both metabolic disorder screening tests and gene mutation analysis may be Clinical presentations of patients with primary performed simultaneously especially for early diagnosis in (familial) and secondary (reactive) HLH are infants presenting with HLH.
    [Show full text]
  • Incidence of Inborn Errors of Metabolism by Expanded Newborn
    Original Article Journal of Inborn Errors of Metabolism & Screening 2016, Volume 4: 1–8 Incidence of Inborn Errors of Metabolism ª The Author(s) 2016 DOI: 10.1177/2326409816669027 by Expanded Newborn Screening iem.sagepub.com in a Mexican Hospital Consuelo Cantu´-Reyna, MD1,2, Luis Manuel Zepeda, MD1,2, Rene´ Montemayor, MD3, Santiago Benavides, MD3, Hector´ Javier Gonza´lez, MD3, Mercedes Va´zquez-Cantu´,BS1,4, and Hector´ Cruz-Camino, BS1,5 Abstract Newborn screening for the detection of inborn errors of metabolism (IEM), endocrinopathies, hemoglobinopathies, and other disorders is a public health initiative aimed at identifying specific diseases in a timely manner. Mexico initiated newborn screening in 1973, but the national incidence of this group of diseases is unknown or uncertain due to the lack of large sample sizes of expanded newborn screening (ENS) programs and lack of related publications. The incidence of a specific group of IEM, endocrinopathies, hemoglobinopathies, and other disorders in newborns was obtained from a Mexican hospital. These newborns were part of a comprehensive ENS program at Ginequito (a private hospital in Mexico), from January 2012 to August 2014. The retrospective study included the examination of 10 000 newborns’ results obtained from the ENS program (comprising the possible detection of more than 50 screened disorders). The findings were the following: 34 newborns were confirmed with an IEM, endocrinopathies, hemoglobinopathies, or other disorders and 68 were identified as carriers. Consequently, the estimated global incidence for those disorders was 3.4 in 1000 newborns; and the carrier prevalence was 6.8 in 1000. Moreover, a 0.04% false-positive rate was unveiled as soon as diagnostic testing revealed negative results.
    [Show full text]
  • Fatal Propionic Acidemia: a Challenging Diagnosis
    Issue: Ir Med J; Vol 112; No. 7; P980 Fatal Propionic Acidemia: A Challenging Diagnosis A. Fulmali, N. Goggin 1. Department of Paediatrics, NDDH, Barnstaple, UK 2. Department of Paediatrics, UHW, Waterford, Ireland Dear Sir, We present a two days old neonate with severe form of propionic acidemia with lethal outcome. Propionic acidemia is an AR disorder, presents in the early neonatal period with progressive encephalopathy and death can occur quickly. A term neonate admitted to NICU on day 2 with poor feeding, lethargy and dehydration. Parents are non- consanguineous and there was no significant family history. Prenatal care had been excellent. Delivery had been uneventful. No resuscitation required with good APGAR scores. Baby had poor suck, lethargy, hypotonia and had lost about 13% of the birth weight. Initial investigations showed hypoglycemia (2.3mmol/L), uremia (8.3mmol/L), hypernatremia (149 mmol/L), severe metabolic acidosis (pH 7.24, HCO3 9.5, BE -18.9) with high anion gap (41) and ketonuria (4+). Hematologic parameters, inflammatory markers and CSF examination were unremarkable. Baby received initial fluid resuscitation and commenced on IV antibiotics. Generalised seizures became eminent at 70 hours of age. Loading doses of phenobarbitone and phenytoin were given. Hepatomegaly of 4cm was spotted on day 4 of life. Very soon baby became encephalopathic requiring invasive ventilation. At this stage clinical features were concerning for metabolic disorder and hence was transferred to tertiary care centre where further investigations showed high ammonia level (1178 μg/dl) and urinary organic acids were suggestive of propionic acidemia. Specific treatment for hyperammonemia and propionic acidemia was started.
    [Show full text]
  • Overview of Newborn Screening for Organic Acidemias – for Parents
    Overview of Newborn Screening for Organic Acidemias – For Parents What is newborn screening? What organic acidemias are on Indiana’s newborn screen? Before babies go home from the nursery, they have a Indiana’s newborn screen tests for several organic small amount of blood taken from their heel to test for acidemias. Some of the organic acidemias on a group of conditions, including organic acidemias. Indi ana’s newborn screen are: Babies who screen positive for an organic acidemia 3-Methylcrotonyl-CoA carboxylase need follow-up tests done to confirm they have the deficiency (also called 3-MCC deficiency) condition. Not all babies with a positive newborn Glutaric acidemia, type I screen will have an organic acidemia. Isovaleric acidemia Methylmalonic acidemia What are organic acidemias? Multiple-CoA carboxylase deficiency Propionic acidemia Organic acidemias are conditions that occur when a person’s body is not able to use protein to make What are the symptoms of organic acidemias? energy. Normally, when we eat, our bodies digest (or break down) food into certain proteins. Those Every child with an organic acidemia is different. proteins are used by our bodies to make energy. Most babies with organic acidemias will look normal Enzymes (special proteins that help our bodies at birth. Symptoms of organic acidemias can appear perform chemical reactions) usually help our bodies shortly after birth, or they may show up later in break down food and create energy. infancy or childhood. Common symptoms of organic A person with an organic acidemia is missing at least acidemias include weakness, vomiting, low blood one enzyme, or his/her enzymes do not work sugar, hypotonia (weak muscles), spasticity (muscle correctly.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE Et Al
    US 20160281 166A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE et al. (43) Pub. Date: Sep. 29, 2016 (54) METHODS AND SYSTEMIS FOR SCREENING Publication Classification DISEASES IN SUBJECTS (51) Int. Cl. (71) Applicant: PARABASE GENOMICS, INC., CI2O I/68 (2006.01) Boston, MA (US) C40B 30/02 (2006.01) (72) Inventors: Arindam BHATTACHARJEE, G06F 9/22 (2006.01) Andover, MA (US); Tanya (52) U.S. Cl. SOKOLSKY, Cambridge, MA (US); CPC ............. CI2O 1/6883 (2013.01); G06F 19/22 Edwin NAYLOR, Mt. Pleasant, SC (2013.01); C40B 30/02 (2013.01); C12O (US); Richard B. PARAD, Newton, 2600/156 (2013.01); C12O 2600/158 MA (US); Evan MAUCELI, (2013.01) Roslindale, MA (US) (21) Appl. No.: 15/078,579 (57) ABSTRACT (22) Filed: Mar. 23, 2016 Related U.S. Application Data The present disclosure provides systems, devices, and meth (60) Provisional application No. 62/136,836, filed on Mar. ods for a fast-turnaround, minimally invasive, and/or cost 23, 2015, provisional application No. 62/137,745, effective assay for Screening diseases, such as genetic dis filed on Mar. 24, 2015. orders and/or pathogens, in Subjects. Patent Application Publication Sep. 29, 2016 Sheet 1 of 23 US 2016/0281166 A1 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS S{}}\\93? sau36 Patent Application Publication Sep. 29, 2016 Sheet 2 of 23 US 2016/0281166 A1 &**** ? ???zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz??º & %&&zzzzzzzzzzzzzzzzzzzzzzz &Sssssssssssssssssssssssssssssssssssssssssssssssssssssssss & s s sS ------------------------------ Patent Application Publication Sep. 29, 2016 Sheet 3 of 23 US 2016/0281166 A1 23 25 20 FG, 2. Patent Application Publication Sep. 29, 2016 Sheet 4 of 23 US 2016/0281166 A1 : S Patent Application Publication Sep.
    [Show full text]
  • Successful Remote Monitoring During COVID-19 Pandemic of Patients
    Successful Remote Monitoring During COVID-19 Pandemic of Patients with Inborn Errors of the Amino acid Metabolism not including PKU from a Single Reference center using Filter Paper Samples Sinziana Stanescu ( [email protected] ) Ramon y Cajal University Hospital: Hospital Universitario Ramon y Cajal https://orcid.org/0000-0003-0340-4580 Amaya Belanger-Quintana Ramon y Cajal University Hospital: Hospital Universitario Ramon y Cajal Francisco Arrieta Ramon y Cajal University Hospital: Hospital Universitario Ramon y Cajal Patricia Alcaide Universidad Autonoma de Madrid Facultad de Ciencias Pedro Ruiz-Sala Universidad Autonoma de Madrid Facultad de Ciencias Research Keywords: COVID-19, inborn errors of metabolism, monitoring, lter samples Posted Date: December 10th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-122663/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/9 Abstract Background. Patients with inborn errors of metabolism (IEM) pose specic management challenges, considering their multisystem involvement. Among them, children and adults with organic acidemias (OA) and other disorders of the amino acid metabolism have a high risk for severe metabolic events that need to be recognized and promptly treated, and therefore require frequent clinical and biochemical evaluations. The novel highly pathogenic SARS-CoV2 virus appeared in Europe in the rst trimester of 2020. This pandemic has a huge impact on the health care systems all over the world, interrupting the follow-up of many chronic diseases. For metabolic patients, travel to reference units may be reduced due to mobility restrictions but more importantly, attendance to medical facilities can be a risk of infection that can be a danger in itself but also trigger a metabolic decompensation.
    [Show full text]
  • Pancytopenia: a Rare Presentation of Late Onset Isovaleric Acidemia
    Karami H et al. IJBC 2020; 12(1): 38-40 Iranian Journal of Blood & Cancer Journal Home Page: www.ijbc.ir Letter to Editor Pancytopenia: A Rare Presentation of Late Onset Isovaleric Acidemia Hossein Karami1, Daniel Zamanfar2, Mohammad Reza Navaifar3, Parastoo Jamallivani4, Kimia Rasoli4, Mohammad Naderisorki1* 1Thalassemia Research Center, Department of Pediatrics Hematology and Oncology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran 2Diabetes Research Center, Department of Pediatrics, Bou Ali Sina Hospital, Mazandaran University of Medical Sciences, Sari, Iran 3Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran 4Student Research Committe, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran ARTICLE INFO *Corresponding author: Mohammad Naderisorki, Article History: Bou Ali Sina Hospital, Mazandaran Received: 27.11.2019 University of Medical Sciences, Pasdaran Boulevard, P.O. Box: 48158- Accepted: 28.12.2019 38477, Sari, Iran Tel/Fax: +98 11 33342331 Email: [email protected] Please cite this article as: Karami H, Zamanfar D, Navaifar MR, Jamallivani P, Rasoli K, Naderisorki M. Pancytopenia: A Rare Presentation of Late Onset Isovaleric Acidemia. IJBC 2020; 12(1): 38-40. Dear Editor, thrombocytopenia and compensated metabolic acidosis. Isovaleric academia was first recognized by Tanaka Biochemical analysis including blood glucose and and colleagues as a new genetic disorder of leucine coagulation profile were within normal limits. Serum metabolism in two siblings in early infancy. There is C-reactive protein, erythrocyte sedimentation rate and Downloaded from ijbc.ir at 19:37 +0330 on Thursday September 30th 2021 a defect in the catabolism of leucine resulting in the lactate dehydrogenase were normal.
    [Show full text]
  • Laboratory Diagnostic Approaches in Metabolic Disorders
    470 Review Article on Inborn Errors of Metabolism Page 1 of 14 Laboratory diagnostic approaches in metabolic disorders Ruben Bonilla Guerrero1, Denise Salazar2, Pranoot Tanpaiboon2,3 1Formerly Quest Diagnostics, Inc., Ruben Bonilla Guerrero, Rancho Santa Margarita, CA, USA; 2Quest Diagnostics, Inc., Denise Salazar and Pranoot Tanpaiboon, San Juan Capistrano, CA, USA; 3Genetics and Metabolism, Children’s National Rare Disease Institute, Washington, DC, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: R Bonilla Guerrero; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Ruben Bonilla Guerrero. Formerly Quest Diagnostics, Inc., Ruben Bonilla Guerrero, 508 Sable, Rancho Santa Margarita, CA 92688, USA. Email: [email protected]. Abstract: The diagnosis of inborn errors of metabolism (IEM) takes many forms. Due to the implementation and advances in newborn screening (NBS), the diagnosis of many IEM has become relatively easy utilizing laboratory biomarkers. For the majority of IEM, early diagnosis prevents the onset of severe clinical symptoms, thus reducing morbidity and mortality. However, due to molecular, biochemical, and clinical variability of IEM, not all disorders included in NBS programs will be detected and diagnosed by screening alone. This article provides a general overview and simplified guidelines for the diagnosis of IEM in patients with and without an acute metabolic decompensation, with early or late onset of clinical symptoms. The proper use of routine laboratory results in the initial patient assessment is also discussed, which can help guide efficient ordering of specialized laboratory tests to confirm a potential diagnosis and initiate treatment as soon as possible.
    [Show full text]
  • Microfilms International 300 N
    INFORMATION TO USERS This reproduction was made from a copy of a document sent to us for microfilming. While the most advanced technology has been used to photograph and reproduce this document, the quality of the reproduction is heavily dependent upon the quality of the material submitted. The following explanation of techniques is provided to help clarify markings or notations which may appear on this reproduction. I. The sign or "target" for pages apparently lacking from the document photographed is "Missing Pagets)". II' it was possible to obtain the missing pagers) or section, they are spliced into the film along with adjacent pages. This may have necessitated cu tting th rough an image and duplicating adjacent pages to assure complete continuity. 2. When an image on the film is obliterated with a round black mark. it is an indication of either blurred copy because of movement during exposure, duplicate copy, or copyrighted materials that should not have been filmed. For blurred pages, J good image of the page can be found in the adjacent frame. If copyrighted materials were deleted, a target note will appear listing the pages in the adjacent frame. 3. When a map, drawing or chart, ctc., is part of the material being photographed. a definite method of "sectioning" the material has been followed. It is customary to begin filming at the upper left hand corner of a large sheet and to continue from left to right in equal sections with small overlaps. If necessary, sectioning is continued again-beginning below the first row and continuing on until complete.
    [Show full text]
  • Care Coordination for California's
    Care Coordination for California’s Children and Youth with Special Health Care Needs: Building Blocks from other States PREPARED FOR THE LUCILE PACKARD FOUNDATION FOR CHILDREN’S HEALTH BY SHARON SILOW-CARROLL BROOKE EHRENPREIS STAN ROSENSTEIN JUNE 2014 Care Coordination for California’s Children and Youth with Special Health Care Needs: Building Blocks from other States June 2014 Contents Acknowledgements ....................................................................................................................................... 1 Introduction .................................................................................................................................................. 3 Care Coordination Approaches in Six Other States ...................................................................................... 6 Decision Points and Considerations for Building a Care Coordination Program .......................................... 7 Eligibility .................................................................................................................................................... 7 Eligibility Considerations for California ................................................................................................. 8 Care Coordination Services and Standards ............................................................................................... 9 Service/Standards Considerations for California ................................................................................ 11 Payment/Reimbursement
    [Show full text]
  • Attachment a Rare and Expensive Disease List As of December 27, 2010 ICD-9 Age Disease Guidelines Code Group 042
    Attachment A Rare and Expensive Disease List as of December 27, 2010 ICD-9 Age Disease Guidelines Code Group 042. Symptomatic HIV disease/AIDS 0-20 (A) A child <18 mos. who is known to be HIV (pediatric) seropositive or born to an HIV-infected mother and: * Has positive results on two separate specimens (excluding cord blood) from any of the following HIV detection tests: --HIV culture (2 separate cultures) --HIV polymerase chain reaction (PCR) --HIV antigen (p24) N.B. Repeated testing in first 6 mos. of life; optimal timing is age 1 month and age 4-6 mos. or * Meets criteria for Acquired Immunodeficiency Syndrome (AIDS) diagnosis based on the 1987 AIDS surveillance case definition V08 Asymptomatic HIV status 0-20 (B) A child >18 mos. born to an HIV-infected (pediatric) mother or any child infected by blood, blood products, or other known modes of transmission (e.g., sexual contact) who: * Is HIV-antibody positive by confirmatory Western blot or immunofluorescense assay (IFA) or * Meets any of the criteria in (A) above 795.71 Infant with inconclusive HIV result 0-12 (E) A child who does not meet the criteria above months who: * Is HIV seropositive by ELISA and confirmatory Western blot or IFA and is 18 mos. or less in age at the time of the test or * Has unknown antibody status, but was born to a mother known to be infected with HIV 270.0 Disturbances of amino-acid 0-20 Clinical history and physical exam; laboratory transport studies supporting diagnosis. Subspecialist Cystinosis consultation note may be required.
    [Show full text]